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to recipient abdominal great vessels using microvascular techniques . Graft function was assessed daily by palpation through the host flank; rejection was taken as the time of complete cessation of myocardial contractions.
mAb Treatment. ART18, ART65, and OX-39 mAbs were administered to experimental animals intravenously at doses of 25-300 wg/kg per d for 10 d starting the day of transplantation. There were 5-9 animals in each experimental group .
Cell Preparations. Single spleen cell (SL) suspensions were prepared by mincing and expressing SL through 60-gauge stainless steel mesh into RPMI-1640 medium (Gibco, Grand Island, NY) supplemented with 5 mM Hepes, 2 MM L-glutamine, and 10% heat-inactivated FCS (Associated Biomedic System, Buffalo, NY) . Erythrocytes were lysed by brieftreatment with 0 .83% Tris-buffered ammonium chloride (pH 7 .21) . Nonadherent T cell-enriched (>95%) populations from nylon wool columns were fractionated into CD4' (T helper/inducer, W3/25') and CD8' (T suppressor/cytotoxic, OX8' ). subsets, as described (11) . Only nonadherent negatively selected T cells (>90% viable, enriched >95% for the desired subpopulation) were adoptively transferred into syngeneic normal rats that received a test graft 24 h later. There were 4-7 animals in each group .
Statistical Analysis. The statistical differences between experimental groups were ascertained using Student's t test.
Results
Binding Parameters for Anti-IL-2-R mAbs . Scatchard analysis revealed distinct binding of iodinated mAbs to G2 target cells . The highest affinity was for OX-39 (kd = 8.26 x 10 -1°), lower for ART 65 (kd = 1.2 x 10 -'), and least for ART 18 (kd = 1.91 x 10-9). In contrast, ART-18 had the maximal number of molecules bound per G2 cell (75,000), followed by OX-39 (61,185), and ART-65 (27,702) . Recent work from this laboratory has demonstrated sparing of Ts by ART-18 treatment (4, 12) . Donor-specific test graft survival is prolonged in naive syngeneic rats to 15 .0 ± 1 and 15.5 ± 0 .9 d after adoptive transfer of 100 x 106 unseparated SL or 50 x 106 CD8' T cells harvested from mAb-conditioned animals 10 d after transplantation, respectively (p < 0.001); CD4+ cells (40-50 x 106) were ineffectual (8.5 ± 0.5 d) . In the present studies, transfer of 100 x 106 SL from ART-65-treated LEW recipients bearing wellfunctioning (LEW x BN)F1 transplants extended the survival of specific test cardiac allografts to 13 .6 t 2 .9 d (p < 0 .001, as compared with untreated controls) . However, when SL from ART-65-treated recipients were separated into highly purified and non-overlapping component parts, the CD4+ subset (50 x 106 cells) conferred profound suppression to normal LEW, with prolongation of (LEW x BN)F1 test grafts to lengths (MST t SD = 45 ± 17 .5 d) unprecedented in our previous experience; transfer of the same number of CD8`cells was less effective (14.5 ± 0 .7 d, p < 0.001). The third-party (WF) test grafts were always rejected within 10 d in the comparable groups of secondary recipients . All the above experiments subsequently were repeated 4-7 times; the results were uniformly the same. Thus, IL-2- R-targeted therapy selectively spares phenotypically distinct populations of Ts : CD8+ in ART-18-treated animals and primarily CD4+ in ART-65-treated hosts.
The Effect of Combined ART-18 Plus ART65 mAb Treatment. Rat recipients of cardiac allografts were treated with a combination of ART18 and ART-65 to target distinct epitopes of the IL-2-R molecule, as well as to influence the selective in vivo effects of mAbs upon host Ts . Concomitant administration of ART-18 and ART-65 for 10 d after transplantation in relatively low doses (25 wg/kg per d), only marginally operative on their own (graft survival = 13 .0 t 1 and 9.5 f 2 .5 d, respectively), proved highly effective, with 3 of 10 cardiac allografts surviving indefinitely, five undergoing rejection at periods >50 d, and the remaining grafts surviving -3 wk (Fig. 1) . Treatment with ART-18 for the first 5 d after transplantation followed by ART-65 therapy for the subsequent 5 d was less striking (16.8 ± 1.6 d) . Thus, ART-18 and ART-65 in combination exert an important synergistic effect in vivo by simultaneously targeting IL-2-R+ cells activated in response to the allogeneic graft. In contrast, therapy combining OX-39 with ART-18 did not improve survival beyond that observed after ART-18 antibody alone (data not shown) .
Discussion
The present studies were designed to compare and correlate the in vitro and in vivo immunosuppressive properties of ART-18, ART-65, and OX-39 (Table I) , noncrossreactive IgGI antibodies that recognize distinct epitopes on the p55 ß chain of the rat Il-2-R (9) . Several questions can be posed based on the results of the experiments.
Why Are mAbs of the Same Isotype and Common Specificityfor thep55 Subunit of the IL-2-R Molecule not Equally Effective In Vivo? These experiments stress the lack of correlation between the in vitro binding parameters of anti-IL-2-R mAbs and their biological efficacy in vivo. ART-18, despite its lower apparent affinity for the receptor, exhibits potent immunosuppressive properties in vivo. In contrast, OX-39 in the same dose did not influence acute rejection of cardiac allografts despite demonstrating the highest affinity for its epitope and covering large numbers of binding sites per target cell in vitro. Although each mAb interacts specifically with a given epitope in vivo, the three-dimensional structure of the epitope may occur on both related and unrelated molecules (13) . For example, ART-62, a mouse anti-rat IgG1 antibody that blocks T cell function and inhibits II-2-dependent T cell proliferation in vitro, lacks biological activity in vivo, despite recognizing broadly the epitope of the rat MHC Class I antigen present on various cells including erythrocytes (12) . It is The In Vitro and In Vivo Properties of Mouse Anti-rat IL-2-R rnAbs ' The in vitro properties of mAbs were tested using the IL-2-dependent rat G2 T cell line . The apparent affinities of mAbs and the number of binding sites on target cells were calculated using Scatchard plot analysis . The effects of mAbs upon IL-2 binding and IL-2-dependent T cell proliferation were tested as described (6-8 possible that OX-39 may be actively "captured" by unrelated cells and tissues expressing the common epitope in vivo, and therefore, it is unable to reach the related targets. Indeed, recent studies demonstrate that this mAb, in contrast to ART18, reacts with N3% of rat thymic dendritic cells and N2To of rat thymocytes (8) .
Is Blocking of T CellActivity by Anti-IL-2-R mAbs Requiredfor Their In Vivo Efects? The present results in an allograft model complement recently reported local graft-vs.-host reaction trials that demonstrate the immunosuppressive efficacy ofART-65, an antibody that in contrast to ART-18 affects neither IL-2 binding nor IL-2-dependent T cell growth (7) . Inhibition of T cell function may not be a prerequisite for successful IL-2-R-targeted therapy as the in vivo mode of action of these mAbs is to eliminate, rather than to inhibit expansion of, IL-2-R+ effector cells. Preliminary data on the use of ART-18 isotype switch variants suggest antibody-dependent cell cytotoxicity to be primarily responsible for the effect observed in our studies (14) . Alternatively, treatment with M7/20, a rat anti-mouse IL-2-R mAb of IgM isotype and binding parameters identical to ART 18, obviated delayed-type hypersensitivity responses in normal but not in complement deficient mice (15) , suggesting that mAbs ideally should fix terminal complement components and inhibit T cell function.
Why Do Anti-IL-2-R mAbs Selectively Spare Phenotypically Distinct TCell Subsets? The heavy glycosylation ofthe Q chain ofthe IL-2-R molecule may explain the discrepancy between the molecular mass of the receptor calculated from the amino acid sequence (30 kD) and the actual molecular mass of the isolated receptor (55 kD) (16) .
Non-random glycosylation ofthe IL-2-R molecule on host lymphocytes may lead to divergent accessibility ofT cell subsets by anti-IL-2-R mAbs with resultant sparing of distinct Ts subpopulations . Thus, ART-18 treatment does not affect the majority of CD8 + Ts but inactivates the CD4 + subset including CD4 + Ts, whereas ART-65 therapy preserves primarily CD4+ Ts. The practical relevance of this observation is of major importance, as sparing of phenotypically distinct Ts may contribute to (17) . It remains to be determined whether the long-lasting therapeutic effect after ART-18 plus ART-65 treatment was achieved by preventing association of p55 R and p75 a chains, so that no high-affinity receptors can be formed .
Summary
The therapeutic efficacies of ART-18, ART-65, and OX-39, mouse antibodies of 
